Aliaksei Holik
Director for Discovery and Translational Science Consulting
Aliaksei is a biomedical scientist with over 15 years of experience in research, specializing in the use of computational biology and machine learning to unravel disease mechanisms, identify and validate therapeutic targets, and prioritize patient populations most likely to benefit from these therapies. With a strong background in Molecular Biology and Genetics, he has utilized a wide array of omics technologies throughout the entire research lifecycle, from experimental design and data generation to analysis and translating results into actionable insights.
As Director for Discovery and Translational Science Consulting Services, Aliaksei assists clients, ranging from top pharmaceutical companies to stealth-mode biotechs in their drug discovery and translational research efforts. His support encompasses data curation, management, and analytics services applied to pre-clinical and clinical datasets in order to understand disease and drug action mechanisms, prioritize targets and indications, and identify molecular and clinical biomarkers to pinpoint patient populations with the most favourable response and safety profiles.
Aliaksei holds a PhD in Cancer Biology from Cardiff University and a BSc in Molecular Biology from the University of Edinburgh.
Latest news
Clarivate Presents Cortellis Regulatory AI Assistant to Cut Through Complexity in Safety and Compliance
Powered by agentic AI, new features help regulatory teams improve accuracy and enable faster, more confident decisions across the product lifecycle London, U.K. — December 4, 2025 — Clarivate Plc…
Clarivate and the Chinese Academy of Sciences Release the 2025 Research Fronts Report
Annual report identifies 110 hot and 18 emerging Research Fronts London, U.K. December 3, 2025. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, and the Chinese Academy…
Clarivate Reveals Global Shifts in Research Collaboration
New report explores multilateral partnerships, Mainland China’s rising influence, and strategic challenges for the U.S. London, U.K. December 2, 2025: Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence,…
